# FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

> **NCT00325403** · PHASE3 · COMPLETED · sponsor: **United Therapeutics** · enrollment: 349 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** Oral treprostinil (UT-15C) Sustained Release Tablets
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00325403
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325403, "FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00325403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*